Cancer Clinical Indication
Preoperative evaluation for patients considered for resection of hepatic/lung metastases in colorectal carcinoma (CRC).
Evaluation of residual structural abnormality on diagnostic imaging following definitive treatments for colorectal carcinoma (CRC).
Staging of proven non-small-cell lung cancer (NSLC) prior to curative or radiotherapy.
Solitary pulmonary nodules not amenable to fine needle aspiration (FNA) or which have failed pathological characterisation.
Restaging of residual mass for Non Hodgkin’s Lymphoma following definitive treatment.
Staging of early stage low grade non Hodgkin’s lymphoma.
Staging of Hodgkin’s Disease
Head and neck
Restaging of residual neck masses in head and neck cancers following radiotherapy/chemotherapy.
Staging for metastatic squamous carcinoma in cervical lymph nodes from unknown primary.
Staging of gastric/oesophageal cancer for curative treatment.
Patients considered for definitive or adjuvant treatment of oligo-metastatic or regional melanoma.
Staging of locally advanced cervical cancer for curative radiation treatment.
Restaging of recurrent ovarian carcinoma being considered for cytoreductive surgery.
All adult oncology PET-CT scan requests will be based on the national clinical indications. Requests for DHB funded PET scans will only be considered from senior medical officers. Cases outside these criteria will be assessed by the Midland Regional Variance Committee.
Requests must be for patients who are eligible to receive publicly funded health and disability services, and being assessed by a hospital specialist to receive publicly funded hospital treatment. Hospital event history may be checked as part of the PET scan request authorising and auditing processes.
Patients receiving services from any private specialist.
Patients receiving services (e.g. assessment, investigations and surgery) through a private service provider.
PET scans request which do not meet nationally agreed clinical indications and which are not approved by the Midland Regional Variance Committee.